As phase three clinical trials for about 10 vaccines are currently underway, DBS Group Research believes that airline food caterer SATS will recover faster than expected.

The brokerage has upgraded the stock to a “buy” call from “hold” and raised its target price to $3.66 from $3.15 previously.

“We are advocating buying ahead of the recovery while valuations are attractive,” DBS analysts Alfie Yeo and Andy Sim write in note dated Oct 1.

To continue reading,

Sign in to access this Premium article.

Subscription entitlements:

Less than $9 per month
3 Simultaneous logins across all devices
Unlimited access to latest and premium articles
Bonus unlimited access to online articles and virtual newspaper on The Edge Malaysia (single login)

Related Stories

Stay updated with Singapore corporate news stories for FREE

Follow our Telegram | Facebook